1. Home
  2. BCG vs COCP Comparison

BCG vs COCP Comparison

Compare BCG & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.15

Market Cap

21.6M

Sector

N/A

ML Signal

HOLD

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$1.17

Market Cap

21.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
COCP
Founded
2016
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
21.6M
IPO Year
2025
2011

Fundamental Metrics

Financial Performance
Metric
BCG
COCP
Price
$1.15
$1.17
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
24.4K
★ 49.3K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 112.50
54.65
EPS
★ 0.08
N/A
Revenue
★ $187,144,000.00
$12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.56
★ N/A
Revenue Growth
★ 10.80
N/A
52 Week Low
$1.11
$0.76
52 Week High
$3.44
$2.03

Technical Indicators

Market Signals
Indicator
BCG
COCP
Relative Strength Index (RSI) 31.86 50.89
Support Level N/A $1.14
Resistance Level $1.58 $1.25
Average True Range (ATR) 0.07 0.08
MACD -0.01 -0.01
Stochastic Oscillator 14.00 24.28

Price Performance

Historical Comparison
BCG
COCP

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: